Portolan Capital Management, LLC Castle Biosciences Inc Transaction History
Portolan Capital Management, LLC
- $1.32 Billion
- Q4 2024
A detailed history of Portolan Capital Management, LLC transactions in Castle Biosciences Inc stock. As of the latest transaction made, Portolan Capital Management, LLC holds 776,579 shares of CSTL stock, worth $21.4 Million. This represents 1.57% of its overall portfolio holdings.
Number of Shares
776,579
Previous 1,255,628
38.15%
Holding current value
$21.4 Million
Previous $35.8 Million
42.21%
% of portfolio
1.57%
Previous 2.85%
Shares
20 transactions
Others Institutions Holding CSTL
# of Institutions
209Shares Held
26.7MCall Options Held
278KPut Options Held
30.3K-
Black Rock Inc. New York, NY3.04MShares$84.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.83MShares$50.6 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.8MShares$49.6 Million0.24% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.44MShares$39.6 Million0.02% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.26MShares$34.8 Million0.61% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $726M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...